Evidence map›Paper›PMID 39349131›Full record

ArticleArchives of biochemistry and biophysics2024

Characterizations of angiotensin-converting enzyme-2 (ACE2) peptidase activity.

Nathalie M Saulnier, Devyn M Thorne, Fariha E Bablu, Alessia M Suzuki, Rafa L Khan, Katelin X Oliveira, Yuichiro J Suzuki

Abstract read
In one paragraph

Article in Archives of biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathalie M SaulnierDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Devyn M ThorneDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Fariha E BabluDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Alessia M SuzukiDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Rafa L KhanDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Katelin X OliveiraDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA.
Yuichiro J SuzukiDepartment of Pharmacology & Physiology, Georgetown University Medical Center, Washington DC 20007, USA. Electronic address: ys82@georgetown.edu.

Funding

Brain ACE2 in Alzheimer's disease in relation to COVID-19R21AG073919 · NIA · GEORGETOWN UNIVERSITY · PI GYCHKA, SERGIY, SUZUKI, YUICHIRO JUSTIN · 2021 to 2022
$342k
Mechanism of pulmonary vascular wall thickening in COVID-19R03AG071596 · NIA · GEORGETOWN UNIVERSITY · PI SUZUKI, YUICHIRO JUSTIN · 2021 to 2022
$151k
NIA NIH HHS R03 AG071596NIA NIH HHS R21 AG073919
6 · The paper itself

Abstract

Angiotensin (Ang) II (1-8) is a potent vasoconstrictor known for its role in hypertension. Angiotensin-converting enzyme (ACE2) converts Ang II (1-8) to a vasodilator Ang (1-7) by removing the carboxy-terminal Phe. ACE2 more recently gained attention as the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused the coronavirus disease 2019 (COVID-19) pandemic. Given the pathophysiological importance of ACE2, the present study examined the mechanism of ACE2 catalytic activity by comparing the ability of angiotensin molecules of various lengths to compete with the artificial fluorogenic substrate. The Fluorimetric SensoLyte 390 ACE2 Activity Assay uses an Mca/Dnp fluorescence resonance energy transfer peptide as the substrate. Results showed that the natural substrate Ang II (1-8) competed with the fluorogenic substrate, reducing the fluorescence signals. Deletion of C-terminal Phe resulted in the loss of the ability to compete with the artificial substrate, as shown by the actions of Ang (1-7), Ang (2-7), and Ang (5-7). By contrast, the loss of N-terminal Asp potentiated the ability to compete with the substrate as seen by the action of Ang III (2-8). However, the loss of two amino acids (Asp-Arg) from the N-terminus reduced the ability to compete with the substrate as observed by the actions of Ang IV (3-8) and Ang (5-8). Ang I (1-10) and Ang (1-9) did not strongly compete with the substrate. Interestingly, shorter peptides Ang (1-5) and Ang (1-4) potentiated the ACE2 activity. These results suggest that Ang II and Ang III are the best natural substrates for ACE2.

Indexed as

Angiotensin-Converting Enzyme 2Angiotensin IAngiotensin IIHumansSARS-CoV-2Substrate SpecificityACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin IAngiotensin IIACE2AngiotensinAngiotensin-converting enzymeCoronavirusCOVID-19PeptidaseSpike protein

Identifiers

PMID39349131
PMCPMC11560506

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.